DELCATH SYSTEMS, INC. (NASDAQ:DCTH) Files An 8-K Regulation FD Disclosure
Item7.01
| Regulation FD Disclosure |
Delcath Systems, Inc. (the Company) is furnishing this Current
Report on Form 8-K in connection with the disclosure of
information contained in an investor presentation (the
Presentation) used by the Company at its 2017 Annual Meeting of
Stockholders. This information may be amended or updated at any
time and from time to time through another Current Report on Form
8-K or other means. A copy of the Presentation is furnished
herewith as Exhibit 99.1 and is incorporated into this Item 7.01
by reference.
The information furnished in this Item 7.01, including Exhibit
99.1, is being furnished and shall not be deemed to be filed for
the purposes of Section18 of the Securities Exchange Act of 1934,
as amended, or otherwise subject to the liabilities of that
section, nor shall it be deemed to be incorporated by reference
into any registration statement filed to the Securities Act of
1933, as amended, except as may be expressly set forth by
specific reference in such filing.
The Company expressly disclaims any obligation to update or
revise any of the information contained in the Presentation.
The Presentation is available on the Companys investor relations
website located at delcath.com/investors, although the Company
reserves the right to discontinue that availability at any time.
| Item8.01. | Other Events. |
As of the close of business on June 5, 2017, there were 374.4
million shares of the Companys common stock outstanding.
| Item9.01 | Financial Statements and Exhibits |
(d) Exhibits
| Exhibit99.1 | Investor Presentation dated June, 2017. |
About DELCATH SYSTEMS, INC. (NASDAQ:DCTH)
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
